Full-Time

Senior Director Biostatistics

Posted on 9/26/2024

Alector

Alector

201-500 employees

Develops therapies for neurodegenerative diseases

Compensation Overview

$280k - $303kAnnually

Senior

Remote in USA

Category
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
R
Data Analysis
Requirements
  • Ph.D. in Statistics or related discipline with 10+ years, or MS with 15+ years of proven experience in the biotechnology or related industry, including interaction and submission experiences with both FDA and EMA.
  • Successful project and people management and expertise in the development of Neuroscience and Rare Disease programs.
  • Thorough knowledge of life cycle management; consistent track record of innovatively applying statistical principles, theories, and concepts to clinical drug development leading to regulatory approvals.
  • Deep hands-on operational experiences in Biostatistics deliverables, including study design, protocol development, CRFs, clinical databases, Statistical Analysis Plans (SAP), SDTM/ADaM datasets, and CSR Tables/Figures/Listings.
  • Up to date knowledge of industry and academic developments in the Neuroscience, and apply them to clinical study design and analysis.
  • Demonstrated innovative and flexible ability and mindset to work in a changing and demanding environment. Exercise good judgment in interpreting, modifying, and adapting procedures, practices, methods, etc. in accordance with existing policies and standards.
  • Demonstrated strong leadership, project management, collaboration, communication, and organization skills.
  • Advanced programming skills in SAS, R and other relevant statistical software solutions.
  • Detailed knowledge of adaptive designs, Bayesian methodology, trial simulation, and complex modeling.
  • Innovative problem-solving capabilities, the agility to respond promptly and completely to time-critical tasks.
Responsibilities
  • As the lead Biostatistician for assigned projects and ensure effective, timely and compliant management and delivery of project goals and accountabilities.
  • Define the statistical strategy and ensure appropriate statistical methodologies are applied to study designs and data analyses for clinical trials.
  • Provide expert statistical input and consultancy to Phase I – IV global clinical trials, lifecycle management activities as well as translational medicine research efforts.
  • Ensure a high degree of rigor is applied to the statistical and scientific decision-making process and outcomes.
  • Collaborate with internal and external collaborators in study design, analysis, reporting, interpretation, and communication of clinical trial results.
  • Author and review critical documents such as briefing documents, protocols, SAP, top-line reports, CSR, and integrated summaries.
  • Support the project team and clinical study team including the derivation of go/no-go criteria, summary reports, and results interpretation.
  • Participate in FDA and other regulatory body interactions (IND/CTA filings, safety reporting).

Alector develops therapies aimed at treating neurodegenerative diseases like Alzheimer's and Parkinson's. The company focuses on research and development of new drug candidates by utilizing knowledge from immunology, neurology, and human genetics. Their approach involves conducting early-stage clinical trials to gather specific data about diseases, which helps improve the chances of success for their treatments. Alector differentiates itself from competitors by emphasizing the body's natural healing processes in their drug development. The company's goal is to create effective treatments for conditions that currently have limited options, while also attracting funding and partnerships through their research findings.

Company Size

201-500

Company Stage

IPO

Total Funding

$189.2M

Headquarters

San Francisco, California

Founded

2013

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in neuroimmunology boosts investment opportunities for Alector.
  • Advancements in antibody engineering enhance Alector's therapeutic development platform.
  • Growing demand for personalized medicine aligns with Alector's genetic-focused strategy.

What critics are saying

  • Failure of AL002 in Phase 2 trial may impact investor confidence.
  • Termination of AL002 program with AbbVie could affect Alector's pipeline.
  • Reliance on external funding increases financial risk if milestones aren't met.

What makes Alector unique

  • Alector leverages state-of-the-art antibody technology for neurodegenerative disease treatment.
  • Strategic alliance with Adimab enhances Alector's antibody discovery and optimization capabilities.
  • Focus on neuroimmunology and human genetics sets Alector apart in drug development.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

3%

2 year growth

0%
MarketScreener
Jan 10th, 2025
Alector, Inc. Announces Termination of Al002 in Collaboration with Abbvie Biotechnology, Ltd

Alector, Inc. was developing AL002, its TREM2 program asset, to treat patients with early Alzheimer?s disease (AD) in collaboration with AbbVie Biotechnology Ltd. under the Co-Development and Option Agreement, dated as of October 16, 2017, between the parties, as amended on February 13, 2023.

ETF Daily News
Dec 21st, 2024
Wellington Management Group LLP Invests $639,000 in Alector, Inc. (NASDAQ:ALEC)

Wellington Management Group LLP invests $639,000 in Alector, Inc. (NASDAQ:ALEC).

GlobeNewswire
Nov 25th, 2024
Alector Announces Results From Al002 Invoke-2 Phase 2 Trial In Individuals With Early Alzheimer'S Disease And Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel, genetically validated therapies for the treatment of neurodegenerative diseases, today announced results from the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). Treatment with AL002 resulted in sustained target engagement and pharmacodynamic responses indicative of microglial activation. However, AL002 failed to meet the primary endpoint of slowing of Alzheimer’s clinical progression as measured by the Clinical Dementia Rating Sum of Boxes (CDR®-SB), and there were no treatment effects that favored AL002 on secondary clinical and functional endpoints. Similarly, there were no significant effects on Alzheimer’s fluid biomarkers favoring AL002, and amyloid PET imaging demonstrated no treatment-related reduction of brain amyloid levels

Benzinga
Nov 14th, 2024
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital - Alector (NASDAQ:ALEC), Hercules Capital (NYSE:HTGC)

SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the Company has entered into a debt

Investing.com
Nov 14th, 2024
Alector secures $50 million credit facility from Hercules Capital

SOUTH SAN FRANCISCO - Alector, Inc. (NASDAQ: ALEC), a company focused on developing therapies for neurodegenerative diseases, has entered into a financing agreement with Hercules Capital, Inc. (NYSE: NYSE:HTGC) for up to $50 million.

INACTIVE